{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2026-09-18", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "spl_product_data_elements": [ "Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow Iohexol Iohexol IOHEXOL IOHEXOL IODINE TROMETHAMINE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID SODIUM HYDROXIDE WATER clear, colorless to pale yellow" ], "boxed_warning": [ "WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF IOHEXOL INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the iohexol, iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of iohexol of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia and brain edema [see Warnings and Precautions (5.1) ]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF IOHEXOL INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures. Intrathecal administration of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia and brain edema. ( 2.2 , 2.8 , 5.1 )" ], "indications_and_usage": [ "1 INDICATIONS AND USAGE Iohexol is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular and body cavity imaging procedures in adults and pediatric patients. ( 1 ) 1.1 Intrathecal Procedures ‡ Iohexol injection is indicated for: Myelography and computerized tomography (CT) myelography (lumbar, thoracic, cervical, total columnar) in adults and pediatric patients aged 2 weeks and older CT cisternography in adults and pediatric patients aged 2 weeks and older 1.2 Intra-arterial Procedures ‡ Iohexol injection is indicated for: Cardiac ventriculography in adults and pediatric patients Aortography including studies of aorta and its branches in adults and pediatric patients Selective coronary arteriography in adults Cerebral arteriography in adults Peripheral arteriography in adults Intra-arterial digital subtraction angiography (IA-DSA) of the head, neck, abdominal, renal and peripheral vessels in adults Pulmonary angiography in pediatric patients 1.3 Intravenous Procedures ‡ Iohexol injection is indicated for: Excretory urography in adults and pediatric patients CT of the head and body in adults and pediatric patients Peripheral venography (phlebography) in adults Intravenous digital subtraction angiography (IV-DSA) of the head, neck, abdominal, renal and peripheral vessels in adults 1.4 Oral or Rectal Procedures ‡ Iohexol injection is indicated for: Radiographic examination of the gastrointestinal (GI) tract in adults and pediatric patients CT of the abdomen and pelvis in conjunction with intravenous administration of iohexol injection in adults and pediatric patients 1.5 Intraarticular Procedures ‡ Iohexol injection is indicated for: Arthrography in adults 1.6 Body Cavity Procedures ‡ Iohexol injection is indicated for: Endoscopic retrograde pancreatography (ERP) and cholangiopancreatography (ERCP) in adults Herniography in adults Hysterosalpingography in adults Voiding cystourethrography (VCU) in pediatric patients ‡ Specific dosage forms, concentrations and presentations of iohexol are recommended for each type of imaging procedure [see Dosage and Administrations (2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9 ) and Warnings and Precautions (5.1 , 5.2) ]." ], "dosage_and_administration": [ "2 DOSAGE AND ADMINISTRATION For each imaging procedure, specific dosage forms, concentrations and presentations are recommended. Individualize the concentration and volume according to the specific dosing tables and accounting for factors such as age, body weight and condition of the patient and the equipment and imaging technique used. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9 ) See full prescribing information for complete dosing and administration information. ( 2 ) 2.1 Important Dosage and Administration Instructions Specific dosage forms, concentrations and presentations of iohexol are recommended for each type of imaging procedure [see Dosage and Administration (2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9 ) and Warnings and Precautions (5.1 , 5.2) ]. Individualize the volume, strength and rate of administration of iohexol injection according to the specific dosing tables [see Dosage and Administration (2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 , 2.8 , 2.9) ] . Consider factors such as age, body weight, vessel size, blood flow rate within the vessel, anticipated pathology, degree and extent of opacification required, structures or area to be examined, disease processes affecting the patient, and equipment and technique to be employed. Hydrate patients before and after administration of iohexol injection [see Warnings and Precautions (5.4) ]. Use aseptic technique for all handling and administration of iohexol injection. Administer iohexol injection at either body (37°C, 98.6°F) or room temperature (20° to 25°C, 68° to 77°F). Do not mix iohexol injection with, or inject in intravenous lines containing, other drugs or total nutritional admixtures. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Each container of iohexol injection in single-dose container is intended for one procedure only. Discard any unused portion. 2.2 Recommended Dosage for Intrathecal Procedures in Adults The recommended doses for intrathecal procedures in adults are shown in Table 1. Administer over 1 minute to 2 minutes. If sequential or repeat examinations are required, allow at least 48 hours for clearance of the drug from the body before repeat administration; however, whenever possible, 5 days to 7 days is recommended. If CT myelography is performed, delay imaging by several hours to reduce the degree of contrast. Table 1: Recommended Concentrations and Volumes of Iohexol Injection for Intrathecal Procedures in Adults Imaging Procedure Injection Type Concentration (mg Iodine/mL) Volume to Administer Lumbar Myelography Lumbar 180 * 10 mL to 17 mL 240 * 7 mL to 12.5 mL Thoracic Myelography Lumbar Cervical 240 * 6 mL to 12.5 mL 300 * 6 mL to 10 mL Cervical Myelography Lumbar 240 * 6 mL to 12.5 mL 300 * 6 mL to 10 mL C1-2 180 * 7 mL to 10 mL 240 * 6 mL to 12.5 mL 300 * 4 mL to 10 mL Total Columnar Myelography Lumbar 240 * 6 mL to 12.5 mL 300 * 6 mL to 10 mL CT Cisternography Lumbar 180 * 10 mL to 17 mL 240 * 7 mL to 12.5 mL * Use single-dose containers. 2.3 Recommended Dosage for Intra-arterial Procedures in Adults The recommended doses for intra-arterial procedures in adults are shown in Table 2. Table 2: Recommended Concentrations and Volumes of Iohexol Injection for Intra-arterial Procedures in Adults Imaging Procedure Concentration (mg Iodine/mL) Volume to Administer per Single Injection for Selective Injection Sites Maximum Cumulative Total Dose Cardiac Ventriculography 350 * 40 mL (Range of 30 mL to 60 mL) may be combined with selective coronary arteriography 250 mL Aortography and Selective Visceral Arteriography 300 * Aorta (aortic arch, ascending aorta): 50 mL to 80 mL Abdominal aorta and its branches (celiac, mesenteric, hepatic and splenic arteries): 30 mL to 60 mL Renal arteries: 5 mL to 15 mL 290 mL 350 * 250 mL Aortic root and arch study when used alone 350 * 50 mL (Range of 20 mL to 75 mL) 250 mL Selective Coronary Arteriography 350 * 5 mL (Range of 3 mL to 14 mL) 250 mL Cerebral Arteriography 300 * Common carotid artery: 6 mL to 12 mL Internal carotid artery: 8 mL to 10 mL External carotid artery: 6 mL to 9 mL Vertebral artery: 6 mL to 10 mL 290 mL Peripheral Arteriography Aortofemoral Runoffs 300 * 30 mL to 90 mL 290 mL 350 * 20 mL to 70 mL 250 mL Selective Arteriogram 300 * 10 mL to 60 mL 290 mL 350 * 10 mL to 30 mL 250 mL IA-DSA (head, neck, abdominal, renal and peripheral vessels) 140 * Aorta: 20 mL to 45 mL at 8 mL/sec to 20 mL/sec Carotid artery: 5 mL to 10 mL at 3 mL/sec to 6 mL/sec Femoral artery: 9 mL to 20 mL at 3 mL/sec to 6 mL/sec Vertebral artery: 4 mL to 10 mL at 2 mL/sec to 8 mL/sec Renal arteries: 6 mL to 12 mL at 3 mL/sec to 6 mL/sec Other branches of aorta (includes subclavian, axillary, innominate and iliac): 8 mL to 25 mL at 3 mL/sec to 10 mL/sec 250 mL * Use single-dose containers. 2.4 Recommended Dosage for Intravenous Procedures in Adults The recommended doses for intravenous procedures in adults are shown in Table 3. Table 3: Recommended Concentrations and Volumes of Iohexol Injection for Intravenous Procedures in Adults Imaging Procedure Concentration (mg Iodine/mL) Volume to Administer Excretory Urography 300 * 0.6 mL/kg to 1.2 mL/kg body weight (maximum dose is 102 mL) 350 * CT Head 240 * 120 mL to 250 mL by infusion 300 ** 70 mL to 150 mL by rapid injection 350 ** 80 mL by rapid injection Body 300 ** 50 mL to 200 mL by rapid injection 350 ** 60 mL to 100 mL by rapid injection Peripheral Venography (phlebography) 240 * 20 mL to 150 mL per leg 300 * 40 mL to 100 mL per leg IV-DSA (head, neck, abdominal, renal and peripheral vessels) 350 * 30 mL to 50 mL at 7.5 mL/sec to 30 mL/sec using a pressure injector Frequently three or more doses may be required; the maximum cumulative total dose is 250 mL * Use single-dose containers. ** Use single-dose containers. 2.5 Recommended Dosage for Oral Procedures in Adults Recommended Dosage for Radiographic Examination of the GI Tract in Adults The recommended dose for radiographic examination of the GI tract in adults is 50 mL to 100 mL of iohexol injection 350 mg iodine/mL administered undiluted orally. Recommended Dosage for CT of the Abdomen and Pelvis in Conjunction with Intravenous Administration of Iohexol Injection in Adults The recommended oral dose using diluted iohexol injection and concurrent intravenous doses for CT of the abdomen and pelvis in adults are shown in Table 4. Table 4: Recommended Concentrations and Volumes of Diluted Iohexol Injection and Concurrent Intravenous Iohexol Injection for CT of the Abdomen and Pelvis in Adults Concentration (mg Iodine/mL) Volume to Administer Administration Instructions Oral Dose Using Diluted Iohexol Injection 6 mg Iodine/mL to 12 mg Iodine/mL of Diluted Iohexol Injection § § See Table 5 for dilution instructions of Iohexol injection 500 mL to 1,000 mL Administer the oral dose all at once or over a period of up to 45 minutes if there is difficulty in consuming the required volume. Use a higher iodine concentration of the diluted product if a smaller volume needs to be administered (see Table 5). Intravenous Dose of Iohexol Injection in Conjunction with Oral Administration 300 ** 100 mL to 150 mL Administer up to 40 minutes AFTER consumption of the oral dose. ** Use single-dose containers. Preparation of Diluted Iohexol Injection for Oral Administration for CT of the Abdomen and Pelvis in Adults Prepare the diluted iohexol injection in water, carbonated beverage, milk, infant formula, or juice just prior to administration according to Table 5. Discard any unused portion after the procedure. Table 5: Volumes of Iohexol Injection and Added Liquid to Dilute Iohexol Injection for Oral Administration for CT of the Abdomen in Adults Concentration of Diluted Iohexol Injection (mg Iodine/mL) Dilution Method 1 Dilution Method 2 Dilution Method 3 Volume of Iohexol Injection 240 mg Iodine/mL (mL) Volume of Added Liquid † (mL) Volume of Iohexol Injection 300 mg Iodine/mL (mL) Volume of Added Liquid † (mL) Volume of Iohexol Injection 350 mg Iodine/mL (mL) Volume of Added Liquid † (mL) 6 25 975 20 980 17 983 9 38 962 30 970 26 974 12 50 950 40 960 35 965 15 63 937 50 950 43 957 18 75 925 60 940 52 948 21 88 912 70 930 60 940 † Use water, carbonated beverage, milk, infant formula, or juice. 2.6 Recommended Dosage for Intraarticular Procedures in Adults The recommended doses for intraarticular procedures in adults are shown in Table 6. Use passive or active manipulation to disperse the medium throughout the joint space. Table 6: Recommended Concentrations and Volumes of Iohexol Injection for Intraarticular Procedures in Adults Imaging Procedure Location Concentration (mg Iodine/mL) Volume to Administer Double Contrast/Single Contrast Arthrography Knee 240 * 5 mL to 15 mL Lower volumes recommended for double-contrast examinations; higher volumes recommended for single-contrast examinations. 300 * 5 mL to 15 mL 350 * 5 mL to 10 mL Shoulder 300 * 10 mL Temporomandibular 300 * 0.5 mL to 1 mL * Use single-dose containers. 2.7 Recommended Dosage for Body Cavity Procedures in Adults The recommended doses for body cavity procedures in adults are shown in Table 7. Volume to administer may vary depending on individual anatomy and/or disease state. Table 7: Recommended Concentrations and Volumes of Iohexol Injection for Body Cavity Procedures in Adults Imaging Procedure Concentration (mg Iodine/mL) Volume to Administer Route of Administration Endoscopic retrograde pancreatography (ERP) and cholangiopancreatography (ERCP) 240 * 10 mL to 50 mL Intraductal Herniography 240 * 15 mL to 20 mL Intraperitoneal 300 * Hysterosalpingography 240 * 50 mL Intrauterine * Use single-dose containers. 2.8 Recommended Dosage for Intrathecal, Intra-arterial and Intravenous Procedures in Pediatric Patients Recommended Dosage for Intrathecal Procedures in Pediatric Patients Aged 2 Weeks and Older Recommended doses based on age for intrathecal procedures in pediatric patients aged 2 weeks and older are shown in Table 8. Administer over 1 minute to 2 minutes. If sequential or repeat examinations are required, allow at least 48 hours for clearance of the drug from the body before repeat administration; however, whenever possible, 5 days to 7 days is recommended. If CT myelography is performed, delay imaging by several hours to reduce the degree of contrast. Table 8: Recommended Concentrations and Volumes of Iohexol Injection Based on Age for Intrathecal Procedure in Pediatric Patients Aged 2 Weeks and Older Imaging Procedure Injection Type Age Concentration (mg Iodine/mL) Volume to Administer Myelography Lumbar Thoracic Cervical Total Columnar CT cisternography Lumbar 2 weeks up to 3 months 180 * 2 mL to 4 mL 3 months up to 36 months 4 mL to 8 mL 3 years up to 7 years 5 mL to 10 mL 7 years up to 13 years 5 mL to 12 mL 13 years to 18 years 6 mL to 15 mL * Use single-dose containers . Recommended Dosage for Intra-arterial Procedures in Pediatric Patients The recommended doses for intra-arterial procedures in pediatric patients are shown in Table 9. Table 9: Recommended Concentrations and Volumes of Iohexol Injection per Body Weight for Intra-arterial Procedures in Pediatric Patients Imaging Procedure Concentration (mg Iodine/mL) Volume per Body Weight to Administer per Single Injection Maximum Cumulative Volume Cardiac Ventriculography 300 * 1.75 mL/kg (Range of 1.5 mL/kg to 2 mL/kg) 6 mL/kg up to a total volume of 290 mL 350 * 1.25 mL/kg (Range of 1 mL/kg to 1.5 mL/kg) 5 mL/kg up to a total volume of 250 mL Aortography (aortic root, aortic arch and descending aorta) 350 * 1 mL/kg 5 mL/kg up to a total volume of 250 mL Pulmonary Angiography 350 * 1 mL/kg 5 mL/kg up to a total volume of 250 mL * Use single-dose containers. Recommended Dosage for Intravenous Procedures in Pediatric Patients The recommended doses for intravenous procedures in pediatric patients are shown in Table 10. Table 10: Recommended Concentrations and Volumes of Iohexol Injection per Body Weight for Intravenous Procedures in Pediatric Patients Imaging Procedure Concentration (mg Iodine/mL) Volume per Body Weight to Administer Excretory Urography 300 * 0.5 mL/kg to 3 mL/kg (Maximum single dose: 116 mL) CT of the Head and Body 240 * 1 mL/kg to 2 mL/kg (with maximum 3 mL/kg) (Maximum single dose: 116 mL) 300 ** * Use single-dose containers. ** Use single-dose containers. 2.9 Recommended Dosage for Oral or Rectal and Body Cavity Procedures in Pediatric Patients Recommended Dosage for Radiographic Examination of the GI Tract in Pediatric Patients The recommended doses for radiographic examination of the GI tract are shown in Table 11. Administer orally or rectally. Table 11: Recommended Concentrations and Volumes of Iohexol Injection Based on Age for Radiographic Examination of the GI Tract in Pediatric Patients Age Concentration (mg iodine/mL) Oral Volume Rectal Volume Less than 3 months 180 * 5 mL to 30 mL May be a larger volume than the volume given orally (up to 300 mL) 3 months to 3 years 180 * , 240 * , or 300 * Up to 60 mL 4 years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL *Use single-dose containers. Recommended Dosage for CT of the Abdomen and Pelvis in Conjunction with Intravenous Administration of Iohexol Injection in Pediatric Patients The recommended oral dose using diluted iohexol injection and concurrent intravenous dose for CT of the abdomen and pelvis in pediatric patients are shown in Table 12. Table 12: Recommended Concentrations and Volumes of Diluted Iohexol Injection and Concurrent Intravenous Iohexol Injection for CT of the Abdomen and Pelvis in Pediatric Patients Concentration (mg Iodine/mL) Volume to Administer Administration Instructions Maximum Dose by Age or Body Weight Oral Dose Using Diluted Iohexol Injection 9 mg Iodine/mL to 21 mg Iodine/mL of Diluted Iohexol Injection § § See Table 13 for Dilution Instructions of Iohexol injection 180 mL to 750 mL Administer the oral dose all at once or over a period of up to 45 minutes if there is difficulty in consuming the required volume. Use a higher iodine concentration of the diluted product if a smaller volume needs to be administered (see Table 13). less than 3 years old: 5 grams iodine 3 years old to 18 years old: 10 grams iodine Intravenous Dose in Conjunction with Oral Administration 240 ** or 300 ** 2 mL/kg body weight (with a range of 1 mL/kg to 2 mL/kg) Administer up to 60 minutes AFTER consumption of the oral dose. 3 mL/kg (maximum single dose: 116 mL) ** Use single-dose containers. Preparation of Diluted Iohexol Injection for Oral Administration for CT of the Abdomen and Pelvis in Pediatric Patients Prepare the diluted iohexol injection in water, carbonated beverage, milk, infant formula, or juice just prior to administration according to Table 13. Discard any unused portion after the procedure. Table 13: Volumes of Iohexol Injection and Added Liquid to Dilute Iohexol Injection for Oral Administration for CT of the Abdomen and Pelvis in Pediatric Patients Concentration of Diluted Iohexol Injection (mg Iodine/mL) Dilution Method 1 Dilution Method 2 Dilution Method 3 Volume of Iohexol Injection 240 mg Iodine/mL (mL) Volume of Added Liquid † (mL) Volume of Iohexol Injection 300 mg Iodine/mL (mL) Volume of Added Liquid † (mL) Volume of Iohexol Injection 350 mg Iodine/mL (mL) Volume of Added Liquid † (mL) 6 25 975 20 980 17 983 9 38 962 30 970 26 974 12 50 950 40 960 35 965 15 63 937 50 950 43 957 18 75 925 60 940 52 948 21 88 912 70 930 60 940 † Use water, carbonated beverage, milk, infant formula, or juice. Recommended Dosage for Voiding Cystourethrography in Pediatric Patients Voiding cystourethrography (VCU) can be performed in conjunction with excretory urography [see Dosage and Administration (2.8) ] . The concentration of diluted iohexol injection may vary depending upon the patient’s size and age and with the technique and equipment used. Volume ranges of diluted iohexol injection 50 mg iodine/mL and 100 mg iodine/mL are shown in Table 14. Dilute iohexol injection with Sterile Water for Injection according to Table 15, utilizing aseptic technique, just prior to use. Discard any unused portion after the procedure. Table 14: Volume Ranges of Diluted Iohexol Injection for VCU in Pediatric Patients Concentration of Diluted Iohexol Injection § (mg Iodine/mL) Volume to Administer 50 50 mL to 600 mL by intravesical administration 100 50 mL to 300 mL by intravesical administration § See Table 15 below for dilution instructions of iohexol injection. Table 15: Volumes of Iohexol Injection and Sterile Water for Injection to Dilute Iohexol Injection for VCU in Pediatric Patients Concentration of Diluted Iohexol Injection (mg Iodine/mL) Dilution Method 1 Dilution Method 2 Dilution Method 3 Volume of Iohexol Injection 240 mg Iodine/mL (mL) Volume of Sterile Water for Injection (mL) Volume of Iohexol Injection 300 mg Iodine/mL (mL) Volume of Sterile Water for Injection (mL) Volume of Iohexol Injection 350 mg Iodine/mL (mL) Volume of Sterile Water for Injection (mL) 50 100 380 100 500 100 600 60 100 300 100 400 100 483 70 100 243 100 330 100 400 80 100 200 100 275 100 338 90 100 167 100 233 100 289 100 100 140 100 200 100 250" ], "dosage_and_administration_table": [ "
Imaging ProcedureInjection TypeConcentration(mg Iodine/mL)Volume to Administer
Lumbar MyelographyLumbar180*10 mL to 17 mL
240*7 mL to 12.5 mL
Thoracic MyelographyLumbarCervical240*6 mL to 12.5 mL
300*6 mL to 10 mL
Cervical MyelographyLumbar240*6 mL to 12.5 mL
300*6 mL to 10 mL
C1-2180*7 mL to 10 mL
240*6 mL to 12.5 mL
300*4 mL to 10 mL
Total Columnar MyelographyLumbar240*6 mL to 12.5 mL
300*6 mL to 10 mL
CT CisternographyLumbar180*10 mL to 17 mL
240*7 mL to 12.5 mL
*Use single-dose containers.
", "
Imaging ProcedureConcentration (mg Iodine/mL)Volume to Administer per Single Injection for Selective Injection SitesMaximum Cumulative Total Dose
Cardiac Ventriculography350*40 mL (Range of 30 mL to 60 mL)may be combined with selective coronary arteriography250 mL
Aortography and Selective Visceral Arteriography300*Aorta (aortic arch, ascending aorta): 50 mL to 80 mLAbdominal aorta and its branches (celiac, mesenteric, hepatic and splenic arteries): 30 mL to 60 mLRenal arteries: 5 mL to 15 mL290 mL
350*250 mL
Aortic root and arch study when used alone350*50 mL (Range of 20 mL to 75 mL)250 mL
Selective Coronary Arteriography350*5 mL (Range of 3 mL to 14 mL)250 mL
Cerebral Arteriography300*Common carotid artery: 6 mL to 12 mLInternal carotid artery: 8 mL to 10 mLExternal carotid artery: 6 mL to 9 mLVertebral artery: 6 mL to 10 mL290 mL
Peripheral ArteriographyAortofemoral Runoffs300*30 mL to 90 mL290 mL
350*20 mL to 70 mL250 mL
Selective Arteriogram300*10 mL to 60 mL290 mL
350*10 mL to 30 mL250 mL
IA-DSA (head, neck, abdominal, renal and peripheral vessels)140*Aorta: 20 mL to 45 mL at 8 mL/sec to 20 mL/secCarotid artery: 5 mL to 10 mL at 3 mL/sec to 6 mL/secFemoral artery: 9 mL to 20 mL at 3 mL/sec to 6 mL/secVertebral artery: 4 mL to 10 mL at 2 mL/sec to 8 mL/secRenal arteries: 6 mL to 12 mL at 3 mL/sec to 6 mL/secOther branches of aorta (includes subclavian, axillary, innominate and iliac): 8 mL to 25 mL at 3 mL/sec to 10 mL/sec250 mL
*Use single-dose containers.
", "
Imaging ProcedureConcentration (mg Iodine/mL)Volume to Administer
Excretory Urography300*0.6 mL/kg to 1.2 mL/kg body weight (maximum dose is 102 mL)
350*
CTHead240*120 mL to 250 mL by infusion
300**70 mL to 150 mL by rapid injection
350**80 mL by rapid injection
Body300**50 mL to 200 mL by rapid injection
350**60 mL to 100 mL by rapid injection
Peripheral Venography (phlebography)240*20 mL to 150 mL per leg
300*40 mL to 100 mL per leg
IV-DSA (head, neck, abdominal, renal and peripheral vessels)350*30 mL to 50 mL at 7.5 mL/sec to 30 mL/sec using a pressure injectorFrequently three or more doses may be required; the maximum cumulative total dose is 250 mL
*Use single-dose containers.**Use single-dose containers.
", "
Concentration(mg Iodine/mL)Volume to AdministerAdministration Instructions
Oral Dose Using Diluted Iohexol Injection
6 mg Iodine/mL to 12 mg Iodine/mL of Diluted Iohexol Injection§§See Table 5 for dilution instructions of Iohexol injection500 mL to 1,000 mLAdminister the oral dose all at once or over a period of up to 45 minutes if there is difficulty in consuming the required volume.Use a higher iodine concentration of the diluted product if a smaller volume needs to be administered (see Table 5).
Intravenous Dose of Iohexol Injection in Conjunction with Oral Administration
300**100 mL to 150 mLAdminister up to 40 minutes AFTER consumption of the oral dose.
**Use single-dose containers.
", "
Concentration of Diluted Iohexol Injection (mg Iodine/mL)Dilution Method 1Dilution Method 2Dilution Method 3
Volume of Iohexol Injection240 mg Iodine/mL(mL)Volume of Added Liquid†(mL)Volume of Iohexol Injection300 mg Iodine/mL(mL)Volume of Added Liquid†(mL)Volume of Iohexol Injection350 mg Iodine/mL(mL)Volume of Added Liquid†(mL)
6259752098017983
9389623097026974
12509504096035965
15639375095043957
18759256094052948
21889127093060940
†Use water, carbonated beverage, milk, infant formula, or juice.
", "
Imaging ProcedureLocationConcentration(mg Iodine/mL)Volume to AdministerDouble Contrast/Single Contrast
ArthrographyKnee240*5 mL to 15 mLLower volumes recommended for double-contrast examinations; higher volumes recommended for single-contrast examinations.
300*5 mL to 15 mL
350*5 mL to 10 mL
Shoulder300*10 mL
Temporomandibular300*0.5 mL to 1 mL
*Use single-dose containers.
", "
Imaging ProcedureConcentration (mg Iodine/mL)Volume to AdministerRoute of Administration
Endoscopic retrograde pancreatography (ERP) and cholangiopancreatography (ERCP)240*10 mL to 50 mLIntraductal
Herniography240*15 mL to 20 mLIntraperitoneal
300*
Hysterosalpingography240*50 mLIntrauterine
*Use single-dose containers.
", "
Imaging ProcedureInjection TypeAgeConcentration(mg Iodine/mL)Volume to Administer
Myelography LumbarThoracicCervicalTotal Columnar CT cisternographyLumbar2 weeks up to 3 months180*2 mL to 4 mL
3 months up to 36 months4 mL to 8 mL
3 years up to 7 years5 mL to 10 mL
7 years up to 13 years5 mL to 12 mL
13 years to 18 years6 mL to 15 mL
*Use single-dose containers.
", "
Imaging ProcedureConcentration (mg Iodine/mL)Volume per Body Weight to Administer per Single InjectionMaximum Cumulative Volume
Cardiac Ventriculography300*1.75 mL/kg(Range of 1.5 mL/kg to 2 mL/kg)6 mL/kg up to a total volume of 290 mL
350*1.25 mL/kg(Range of 1 mL/kg to 1.5 mL/kg)5 mL/kg up to a total volume of 250 mL
Aortography (aortic root, aortic arch and descending aorta)350*1 mL/kg5 mL/kg up to a total volume of 250 mL
Pulmonary Angiography350*1 mL/kg5 mL/kg up to a total volume of 250 mL
*Use single-dose containers.
", "
Imaging ProcedureConcentration(mg Iodine/mL)Volume per Body Weight to Administer
Excretory Urography300*0.5 mL/kg to 3 mL/kg (Maximum single dose: 116 mL)
CT of the Head and Body240*1 mL/kg to 2 mL/kg (with maximum 3 mL/kg)(Maximum single dose: 116 mL)
300**
*Use single-dose containers.**Use single-dose containers.
", "
AgeConcentration(mg iodine/mL)Oral VolumeRectal Volume
Less than 3 months180*5 mL to 30 mLMay be a larger volume than the volume given orally(up to 300 mL)
3 months to 3 years180*, 240*, or 300*Up to 60 mL
4 years to 10 yearsUp to 80 mL
Greater than 10 yearsUp to 100 mL
*Use single-dose containers.
", "
Concentration(mg Iodine/mL)Volume to AdministerAdministration InstructionsMaximum Dose by Age or Body Weight
Oral Dose Using Diluted Iohexol Injection
9 mg Iodine/mL to 21 mg Iodine/mL of Diluted Iohexol Injection§§See Table 13 for Dilution Instructions of Iohexol injection180 mL to 750 mLAdminister the oral dose all at once or over a period of up to 45 minutes if there is difficulty in consuming the required volume.Use a higher iodine concentration of the diluted product if a smaller volume needs to be administered (see Table 13).less than 3 years old: 5 grams iodine3 years old to 18 years old: 10 grams iodine
Intravenous Dose in Conjunction with Oral Administration
240** or 300**2 mL/kg body weight (with a range of 1 mL/kg to 2 mL/kg)Administer up to 60 minutes AFTER consumption of the oral dose.3 mL/kg (maximum single dose: 116 mL)
**Use single-dose containers.
", "
Concentration of Diluted Iohexol Injection (mg Iodine/mL)Dilution Method 1Dilution Method 2Dilution Method 3
Volume of Iohexol Injection 240 mg Iodine/mL (mL)Volume of Added Liquid† (mL)Volume of Iohexol Injection 300 mg Iodine/mL (mL)Volume of Added Liquid† (mL)Volume of Iohexol Injection 350 mg Iodine/mL (mL)Volume of Added Liquid† (mL)
6259752098017983
9389623097026974
12509504096035965
15639375095043957
18759256094052948
21889127093060940
†Use water, carbonated beverage, milk, infant formula, or juice.
", "
Concentration of Diluted Iohexol Injection§(mg Iodine/mL)Volume to Administer
5050 mL to 600 mL by intravesical administration
10050 mL to 300 mL by intravesical administration
§See Table 15 below for dilution instructions of iohexol injection.
", "
Concentration of Diluted IohexolInjection(mg Iodine/mL)Dilution Method 1Dilution Method 2Dilution Method 3
Volume of Iohexol Injection240 mg Iodine/mL(mL)Volume of Sterile Water for Injection(mL)Volume of Iohexol Injection300 mg Iodine/mL(mL)Volume of Sterile Water for Injection(mL)Volume of Iohexol Injection350 mg Iodine/mL(mL)Volume of Sterile Water for Injection(mL)
50100380100500100600
60100300100400100483
70100243100330100400
80100200100275100338
90100167100233100289
100100140100200100250
" ], "dosage_forms_and_strengths": [ "3 DOSAGE FORMS AND STRENGTHS Injection: Clear, colorless to pale yellow solution available in the following presentations: Dosage Form Concentration (mg of iodine/mL) Package Size Package Type Injection 300 50 mL, 75 mL and 100 mL Single-Dose Bottle 350 50 mL, 75 mL and 100 mL Injection: 300 mg iodine/mL and 350 mg iodine/mL in single-dose bottles. ( 3 )" ], "dosage_forms_and_strengths_table": [ "
Dosage FormConcentration(mg of iodine/mL)Package SizePackage Type
Injection30050 mL, 75 mL and 100 mLSingle-Dose Bottle
350 50 mL, 75 mL and 100 mL
" ], "contraindications": [ "4 CONTRAINDICATIONS Iohexol for hysterosalpingography is contraindicated during pregnancy or suspected pregnancy, menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract including the external genitalia and when reproductive tract neoplasia is known or suspected because of the risk of peritoneal spread of neoplasm. Hysterosalpingography during pregnancy (or suspected pregnancy), menstruation (or when menstruation is imminent), within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract, including the external genitalia and when reproductive tract neoplasia is known or suspected. ( 4 )" ], "warnings_and_cautions": [ "5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Always have emergency equipment and trained personnel available. ( 5.3 ) Acute Kidney Injury: Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk. ( 5.4 ) Cardiovascular Adverse Reactions: Hemodynamic disturbances including shock and cardiac arrest may occur during or after administration. ( 5.5 ) Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity. ( 5.9 ) 5.1 Risks Associated with Intrathecal Administration of Iohexol Injection 140 mg Iodine/mL and 350 mg Iodine/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of iohexol injection of a wrong iodine concentration, even if inadvertent, can cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia and brain edema. 5.2 Risks Associated with Parenteral Administration of Iohexol Oral Solution Adverse reactions such as hemolysis may occur if iohexol oral solution is administered intravenously or intraarterially due to low osmolality [see Description (11) ] . Iohexol oral solution is for oral use only. 5.3 Hypersensitivity Reactions Iohexol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema and shock. Most severe reactions develop shortly after the start of the injection (within 1 to 3 minutes), but delayed reactions can also occur. There is an increased risk in patients with a history of a previous reaction to contrast agent and known allergic disorders (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities. Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions but may reduce both their incidence and severity. Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iohexol injection administration. Monitor all patients for hypersensitivity reactions. 5.4 Acute Kidney Injury Acute kidney injury, including renal failure, may occur after parenteral administration of iohexol injection. Risk factors include: pre-existing renal impairment, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant use of nephrotoxic or diuretic medications, multiple myeloma/paraproteinaceous diseases, repetitive and/or large doses of an iodinated contrast agent. Use the lowest necessary dose of iohexol in patients with renal impairment. Adequately hydrate patients prior to and following parenteral administration of iohexol injection. Do not use laxatives, diuretics, or preparatory dehydration prior to iohexol injection administration. 5.5 Cardiovascular Adverse Reactions Life-threatening or fatal cardiovascular reactions including hypotension, shock, cardiac arrest have occurred with the parenteral administration of iohexol injection. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Cardiac decompensation, serious arrhythmias and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography. Based on clinical literature, reported deaths from the administration of iodinated contrast agents range from 6.6 per million (0.00066%) to 1 in 10,000 (0.01%). Use the lowest necessary dose of iohexol in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available. Monitor all patients for severe cardiovascular reactions. 5.6 Thromboembolic Events Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiography procedures with iodinated contrast agents including iohexol. During these procedures, increased thrombosis and activation of the complement system occurs. Risk factors for thromboembolic events include: length of procedure, catheter and syringe material, underlying disease state and concomitant medications. To minimize thromboembolic events, use meticulous angiographic techniques and minimize the length of the procedure. Avoid blood remaining in contact with syringes containing iohexol, which increases the risk of clotting. Avoid angiocardiography in patients with homocystinuria because of the risk of inducing thrombosis and embolism. 5.7 Extravasation and Injection Site Reactions Extravasation of iohexol during intravenous or intra-arterial injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravenous or intra-arterial placement of catheters prior to injection. Monitor patients for extravasation and advise patients to seek medical care for progression of symptoms. 5.8 Thyroid Storm in Patients with Hyperthyroidism Thyroid storm has occurred after the intravenous or intra-arterial use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of iohexol. 5.9 Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media (ICM) in pediatric patients 0 to 3 years of age. Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units and congenital cardiac conditions are associated with an increased risk of hypothyroidism after ICM exposure. Pediatric patients with congenital cardiac conditions may be at the greatest risk given that they often require high doses of contrast during invasive cardiac procedures. An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy. After exposure to ICM, individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates. 5.10 Hypertensive Crisis in Patients with Pheochromocytoma Hypertensive crisis has occurred after the use of iodinated contrast agents in patient with pheochromocytoma. Monitor patients when administering iohexol injection intravenously or intra-arterially if pheochromocytoma or catecholamine-secreting paragangliomas are suspected. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure and have measures for treatment of a hypertensive crisis readily available. 5.11 Sickle Cell Crisis in Patients with Sickle Cell Disease Iodinated contrast agents when administered intravenously or intra-arterially may promote sickling in individuals who are homozygous for sickle cell disease. Hydrate patients prior to and following iohexol injection administration and use iohexol only if the necessary imaging information cannot be obtained with alternative imaging modalities. 5.12 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravenous or intra-arterial contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of contrast agents; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering iohexol injection to patients with a history of a severe cutaneous adverse reaction to iohexol. 5.13 Interference with Laboratory Test Iohexol can interfere with protein-bound iodine test [see Drug Interactions (7.2) ]. 5.14 Increased Risk of Seizures with Intrathecal Administration Focal and generalized motor seizures have been reported after intrathecal use of iodinated contrast agents. In several of the cases, higher than recommended doses were administered. Use of medications that may lower the seizure threshold (phenothiazine derivatives, including those used for their antihistaminic properties; tricyclic antidepressants; MAO inhibitors; CNS stimulants; analeptics; antipsychotic agents) should be carefully evaluated. Consider discontinuing these agents at least 48 hours before and for at least 24 hours following intrathecal administration of iohexol injection." ], "adverse_reactions": [ "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Intrathecal Administration of Iohexol Injection 140 mg Iodine/mL and 350 mg Iodine/mL [see Warnings and Precautions (5.1) ] Risks Associated with Parenteral Administration of Iohexol Oral Solution [see Warnings and Precautions (5.2) ] Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Acute Kidney Injury [see Warnings and Precautions (5.4) ] Cardiovascular Adverse Reactions [see Warnings and Precautions (5.5) ] Thromboembolic Events [see Warnings and Precautions (5.6) ] Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age [see Warnings and Precautions (5.9) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.12) ] Most common adverse reactions (incidence ≥ 1%) in adult patients Intrathecal: Headaches, pain including backache, neckache, stiffness and neuralgia, nausea, vomiting, dizziness. Intra-arterial or intravenous: Pain, vision abnormalities (including blurred vision and photomas), headache, taste perversion, arrhythmias including premature ventricular contractions (PVCs) and premature atrial contractions (PACs), angina/chest pain, nausea. Oral: Diarrhea, nausea, vomiting, abdominal pain, flatulence, headache. Body Cavity: Pain, swelling, heat sensation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Intrathecal Administration Adults Adverse reactions (≥ 1%) in 1,531 adult patients following intrathecal administration of iohexol injection in clinical trials are presented in Table 16. Table 16: Adverse Reactions (≥ 1%) in Adult Patients Following Intrathecal Administration of Iohexol Injection in Clinical Trials System Organ Class Adverse Reaction Incidence N = 1,531 Nervous system disorders Headaches 18% Musculoskeletal and connective tissue disorders Pain including backache, neckache, stiffness, neuralgia 8% Gastrointestinal disorders Nausea 6% Vomiting 3% Nervous System disorders Dizziness 2% Other adverse reactions (< 1%) were: Ear and labyrinth disorders : tinnitus, vertigo Eye disorders : photophobia General disorders and administration site conditions : sensation of heat Metabolism and nutrition disorders : loss of appetite Musculoskeletal and connective tissue disorders : feeling of heaviness Nervous system disorders : drowsiness, hypertonia, neuralgia, neurological changes, paresthesia, syncope Renal and urinary disorders : difficulty in micturition Skin and subcutaneous tissue disorders : sweating Vascular disorders : hypertension, hypotension Pediatric Patients The adverse reactions reported in pediatric patients following intrathecal administration of iohexol injection were generally similar to those reported in adults. A total of 152 pediatric patients were administered iohexol injection 180 mg iodine/mL intrathecally by lumbar puncture for pediatric myelography in clinical trials. Adverse reactions (≥ 1%) are presented in Table 17. Table 17: Adverse Reactions (≥ 1%) in Pediatric Patients Following Intrathecal Administration of Iohexol Injection 180 mg iodine/mL by Lumbar Puncture for Myelography in Clinical Trials System Organ Class Adverse Reaction Incidence N = 152 Nervous system disorders Headache 9% Gastrointestinal disorders Vomiting 6% Musculoskeletal and connective tissue disorders Backache 1.3% Other adverse reactions (< 1%) were: Gastrointestinal disorders: stomachache General disorders and administration site conditions: fever Nervous system disorders : neurological changes Psychiatric disorders : visual hallucination Skin and subcutaneous tissue disorders : hives Intra-arterial or Intravenous Administration Adults Adverse reactions (≥ 1%) in 1,485 adult patients following intra-arterial or intravenous administration of iohexol injection in clinical trials are presented in Table 18. Table 18: Adverse Reactions (≥ 1%) in Adult Patients Following Intra-arterial or Intravenous Administration of Iohexol Injection in Clinical Trials System Organ Class Adverse Reaction Incidence (N = 1,485) Cardiac disorders Arrhythmias including PVCs and PACs 2% Nervous system disorders Pain 3% Vision abnormalities including blurred vision and photomas 2% Taste perversion 1% Gastrointestinal disorders Nausea 2% Other adverse reactions (< 1%) were: Cardiac disorders: hypotension, cardiac failure, asystole, bradycardia, tachycardia, vasovagal reaction Respiratory, thoracic and mediastinal disorders: dyspnea, rhinitis, coughing, laryngitis Gastrointestinal disorders : vomiting, diarrhea, dyspepsia, cramp, dry mouth General disorders and administration site conditions: fever, shivering Nervous system disorders: cerebral infarction, convulsion, hemiparesis, motor and speech dysfunction, nystagmus, paresthesia, somnolence, transient ischemic attack, vertigo including dizziness and lightheadedness Musculoskeletal and connective tissue disorders: still neck Skin and subcutaneous tissue disorders : urticaria, abscess, pruritus, purpura Psychiatric disorders : anxiety, syncope Pediatric Patients Adverse reactions reported in pediatric patients following intra-arterial or intravenous administration of iohexol injection were generally similar in quality and frequency to those reported in adults. A total of 391 pediatric patients in clinical trials were administered iohexol injection 240 mg iodine/mL, 300 mg iodine/mL, or 350 mg iodine/mL by intra-arterial or intravenous injection for pediatric cardiac ventriculography, excretory urography and CT head imaging. Adverse reactions (≥ 1%) were vomiting (2%) and nausea (1%). Other adverse reactions (< 1%) were: Cardiac disorders: Ventricular tachycardia, 2:1 heart block, hypertension, anemia General disorders and administration site conditions: Pain, fever Nervous system disorders: Convulsion, taste abnormality Respiratory, thoracic and mediastinal disorders: Congestion, apnea Endocrine disorders: Hypoglycemia Skin and subcutaneous tissue disorders: Rash Oral or Rectal Administration for Examination of the Gastrointestinal Tract Adults A total of 54 adult patients were administered undiluted iohexol injection 350 mg iodine/mL by oral route for radiographic examination of the gastrointestinal tract in clinical trials. Adverse reactions (≥ 1%) are presented in Table 19. Table 19: Adverse Reactions (≥ 1%) in Adult Patients Following Oral Administration of Undiluted Iohexol Injection 350 mg Iodine/mL in Clinical Trials System Organ Class Adverse Reaction Incidence N = 54 Gastrointestinal disorders Diarrhea 42% Nausea 15% Vomiting 11% Abdominal Pain 7% Flatulence 2% Nervous system disorders Headache 2% Pediatrics Patients A total of 58 pediatric patients were administered iohexol injection by oral or rectal administration in clinical trials. Adverse reactions (≥ 1%) are presented in Table 20. Table 20: Adverse Reactions (≥ 1%) in Pediatric Patients Following Oral or Rectal Administration of Iohexol Injection in Clinical Trials System Organ Class Adverse Reaction Incidence N = 58 Gastrointestinal disorders Diarrhea 36% Vomiting 9% Nausea 5% Abdominal pain 2% General disorders and administration site conditions Fever 5% Skin and subcutaneous tissue disorders Urticaria 2% Vascular disorders Hypotension 2% Oral Administration for CT of the Abdomen in Conjunction with Intravenous Administration Adults A total of 44 adult patients received diluted iohexol injection (4 mg iodine/mL to 9 mg iodine/mL) by oral route in conjunction with intravenously injected iohexol 300 mg iodine/mL for CT examination of the abdomen in clinical trials. Adverse reactions (≥ 1%) were limited to a single report of vomiting (2.3%). Pediatric Patients A total of 69 pediatric patients received diluted iohexol injection (9 mg iodine/mL to 29 mg iodine/mL) by oral route in conjunction with intravenously administered iohexol injection 240 mg iodine/mL or iohexol injection 300 mg iodine/mL for CT examination of the abdomen in clinical trials. Adverse reactions (≥ 1%) were limited to a single report of vomiting (1.4%). Intraarticular Administration Arthrography in Adults A total of 285 adult patients received iohexol injection 240 mg iodine/mL, 300 mg iodine/mL, or 350 mg iodine/mL for various body cavity examinations in clinical trials. The most frequent adverse reactions (≥ 1%) were administration site pain (26%) and swelling (22%) in arthrography. Patients also experienced heat (7%). Body Cavity Use VCU in Pediatric Patients No new adverse reactions associated with the use of iohexol injection for VCU procedures were reported in 51 pediatric patients studied. 6.2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of iohexol injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. General Immune system disorders: Hypersensitivity reactions, anaphylactic or anaphylactoid reactions, anaphylactic or anaphylactoid shock including life-threatening or fatal anaphylaxis General disorders and administration site conditions: Pyrexia, chills, pain and discomfort, asthenia, administration site conditions including extravasation Intrathecal Administration Nervous system disorders: Meningism, aseptic meningitis, seizures or status epilepticus, disorientation, coma, depressed or loss of consciousness, transient contrast-induced toxic encephalopathy (including amnesia, hallucination, paralysis, paresis, speech disorder, aphasia, dysarthria), restlessness, tremors, hypoesthesia Musculoskeletal and connective tissue disorders : Pain, muscle spasms or spasticity Psychiatric disorders: Confusional state, agitation, anxiety Eye disorders: Transient visual impairment including cortical blindness Renal and urinary disorders: Acute kidney injury Intra-arterial or Intravenous Administration Cardiac disorders: Severe cardiac complications (including cardiac arrest, cardiopulmonary arrest), shock, peripheral vasodilatation, palpitations, vasospasm including spasm of coronary arteries, myocardial infarction, syncope, cyanosis, pallor, flushing, chest pain Vascular disorders: Vasospasm and thrombophlebitis following intravenous injection Blood and lymphatic system disorders: Neutropenia Nervous system disorders: Disorientation, coma, depressed or loss of consciousness, transient contrast-induced toxic encephalopathy (including amnesia, hallucination, paralysis, paresis, speech disorder, aphasia, dysarthria), restlessness, tremors, hypoesthesia Psychiatric disorders: Confusional state, agitation Eye disorders: Eye irritation or itchiness, periorbital edema, ocular or conjunctival hyperemia, lacrimation Renal and urinary disorders: Acute kidney injury, toxic nephropathy (CIN), transient proteinuria, oliguria or anuria, increased serum creatinine Gastrointestinal disorders: Abdominal pain, pancreatitis aggravated, salivary gland enlargement Endocrine disorders: Hyperthyroidism, hypothyroidism Respiratory, thoracic and mediastinal disorders: Respiratory distress, respiratory failure, pulmonary edema, bronchospasm, laryngospasm, throat irritation, throat tightness, laryngeal edema, wheezing, chest discomfort, asthmatic attack Skin and subcutaneous tissue disorders: Contrast media reactions range from mild (e.g., pleomorphic rashes, drug eruption, erythema and skin discoloration, blisters, hyperhidrosis, angioedema, localized areas of edema) to severe (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis [SJS/TEN], bullous or exfoliative dermatitis, acute generalized exanthematous pustulosis [AGEP] and drug reaction with eosinophilia and systemic symptoms [DRESS]) Oral Administration Gastrointestinal disorders: Dysphagia, abdominal pain Body Cavity Administration Gastrointestinal disorders: Pancreatitis Musculoskeletal and connective tissue disorders: Arthritis (arthrography) Hysterosalpingography: Injection of iohexol for hysterosalpingography is associated with immediate, transient pain. Monitor injection pressure and volume instilled to minimize pain and to avoid disruptive distention of the uterus and fallopian tubes. Fluoroscopic monitoring is recommended. Nervous system disorders: Pain (49%), somnolence and fever each with an individual incidence of 3% Gastrointestinal disorders: Nausea (3%)" ], "adverse_reactions_table": [ "
System Organ ClassAdverse ReactionIncidenceN = 1,531
Nervous system disordersHeadaches18%
Musculoskeletal and connective tissue disordersPain including backache, neckache, stiffness, neuralgia8%
Gastrointestinal disordersNausea6%
Vomiting3%
Nervous System disordersDizziness2%
", "
System Organ ClassAdverse ReactionIncidenceN = 152
Nervous system disordersHeadache9%
Gastrointestinal disordersVomiting6%
Musculoskeletal and connective tissue disordersBackache1.3%
", "
System Organ ClassAdverse ReactionIncidence(N = 1,485)
Cardiac disordersArrhythmias including PVCs and PACs2%
Nervous system disordersPain3%
Vision abnormalities including blurred vision and photomas2%
Taste perversion1%
Gastrointestinal disordersNausea2%
", "
System Organ ClassAdverse ReactionIncidence N = 54
Gastrointestinal disordersDiarrhea42%
Nausea15%
Vomiting11%
Abdominal Pain7%
Flatulence2%
Nervous system disordersHeadache2%
", "
System Organ ClassAdverse ReactionIncidence N = 58
Gastrointestinal disordersDiarrhea36%
Vomiting9%
Nausea5%
Abdominal pain2%
General disorders and administration site conditionsFever5%
Skin and subcutaneous tissue disordersUrticaria2%
Vascular disordersHypotension2%
" ], "drug_interactions": [ "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iohexol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable. Radioactive Iodine Iohexol may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post iohexol injection. 7.2 Drug-Laboratory Test Interactions Protein-Bound Iodine Test Iodinated contrast agents, including iohexol, will temporarily increase protein-bound iodine in blood. Do not perform protein-bound iodine test for at least 16 days following administration of iohexol injection. However, thyroid function tests that do not depend on iodine estimation, e.g., T3 resin uptake or direct thyroxine assays, are not affected." ], "use_in_specific_populations": [ "8 USE IN SPECIFIC POPULATIONS Lactation: A lactating woman may pump and discard breast milk for 10 hours after iohexol injection administration. ( 8.2 ) 8.1 Pregnancy Risk Summary Hysterosalpingography is contraindicated in pregnant women due to the potential risk to the fetus from an intrauterine procedure [see Contraindications (4) ]. There are no data with iohexol use in pregnant women to inform any drug-associated risks. Iohexol crosses the placenta and reaches fetal tissues in small amounts (see Data) . In animal reproduction studies, no developmental toxicity occurred with intravenous iohexol administration to rats and rabbits at doses up to 0.4 (rat) and 0.5 (rabbit) times the maximum recommended human intravenous dose (see Data) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Literature reports show that intravenously administered iohexol crosses the placenta and is visualized in the digestive tract of exposed infants after birth. Animal Data Iohexol was neither embryotoxic nor teratogenic in either rats or rabbits at the following dose levels tested: 1 g iodine/kg, 2 g iodine/kg, 4 g iodine/kg in rats, administered intravenously to 3 groups of 25 dams once daily during days 6 through 15 of pregnancy; 0.3 g iodine/kg, 1 g iodine/kg, 2.5 g iodine/kg in rabbits, administered intravenously to 3 groups of 18 rabbits dosed once a day during days 6 through 18 of pregnancy. 8.2 Lactation Risk Summary Published literature reports that breast feeding after intravenous iohexol administration to the mother would result in the infant receiving an oral dose of approximately 0.7% of the maternal intravenous dose; however, lactation studies have not been conducted with oral, intrathecal, or intracavity administration of iohexol. There is no information on the effects of the drug on the breastfed infant or on milk production. Iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from the gastrointestinal tract of a breastfed infant. Exposure to iohexol to a breastfed infant can be minimized by temporary discontinuation of breastfeeding (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for iohexol and any potential adverse effects on the breastfed infant from iohexol or from the underlying maternal condition. Clinical Considerations Interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because the potential exposure of the breastfed infant to iodine is small. However, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 10 hours (approximately 5 elimination half-lives) after iohexol injection administration to minimize drug exposure to a breastfed infant. 8.4 Pediatric Use Intrathecal Use The safety and effectiveness of iohexol have been established in pediatric patients aged 2 weeks and older for myelography and CT myelography (lumbar, thoracic, cervical, total columnar) and for CT cisternography. Use of iohexol is supported by controlled clinical studies in adults for myelography, in addition to clinical studies in pediatric patients undergoing myelography. The safety and effectiveness of iohexol have not been established for intrathecal use in pediatric patients less than 2 weeks of age. The safety and effectiveness of iohexol for CT cerebral ventriculography have not been established in pediatric patients. Intra-arterial or Intravenous Use Cardiac Ventriculography, Aortography and Pulmonary Angiography The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for cardiac ventriculography, aortography and pulmonary angiography. Use of iohexol is supported by controlled clinical studies in adults for cardiac ventriculography and aortography, in addition to controlled clinical studies in pediatric patients undergoing cardiac ventriculography, including aortography. Excretory Urography The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for excretory urography. Use of iohexol is supported by controlled clinical studies in adults for urography, in addition to controlled clinical studies in pediatric patients undergoing urography and clinical safety data in pediatric patients down to birth. CT of the Head and Body The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for CT imaging of the head and body. Use of iohexol is supported by controlled clinical studies in adults for head and body CT, in addition to clinical studies in pediatric patients undergoing head CT and in 69 pediatric patients undergoing CT of the abdomen after oral administration of diluted iohexol plus intravenous administration of iohexol injection. Selective Coronary Arteriography, Cerebral and Peripheral Arteriography, Intra-arterial Digital Subtraction Angiography, Peripheral Venography and Intravenous Digital Subtraction Angiography The safety and effectiveness of iohexol have not been established in pediatric patients for selective coronary arteriography, cerebral or peripheral arteriography, intra-arterial digital subtraction angiography, peripheral venography and intravenous digital subtraction angiography. Oral or Rectal Use Examination of the GI Tract The safety and effectiveness of iohexol have been established in pediatric patients, from birth to 17 years of age for examination of the GI tract. Use of iohexol is supported by controlled studies in adults for examination of the GI tract, in addition to clinical studies in pediatric patients undergoing examination of the GI tract. CT of the Abdomen and Pelvis in Conjunction with Intravenous Use The safety and effectiveness of iohexol for CT of the abdomen and pelvis have been established in pediatric patients from birth to 17 years of age. Use is supported by clinical trials in adults, in addition to clinical studies in 69 pediatric patients undergoing CT of the abdomen. Intraarticular Use The safety and effectiveness of iohexol have not been established in pediatric patients for arthrography. Body Cavity Use Voiding Cystourethrography Iohexol is indicated for use in pediatric patients from birth to 17 years of age for voiding cystourethrography (VCU). Use for voiding cystourethrography is supported by clinical studies in 51 pediatric patients undergoing VCU. ERCP, Herniography, and Hysterosalpingography The safety and effectiveness of iohexol have not been established in pediatric patients for ERCP, herniography, or hysterosalpingography. In general, the frequency of adverse reactions in pediatric patients was similar to that seen in adults [ s ee Adverse Reactions (6.1) ] . Pediatric patients at higher risk of experiencing adverse events during contrast-medium administration may include those having asthma, a sensitivity to medication and/or allergens, congestive heart failure, a serum creatinine greater than 1.5 mg/dL or those less than 12 months of age. Thyroid function tests indicative of thyroid dysfunction, characterized by hypothyroidism or transient thyroid suppression have been reported following iodinated contrast media administration in pediatric patients, including term and preterm neonates. Some patients were treated for hypothyroidism. After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0 to 3 years of age based on underlying risk factors, especially in term and preterm neonates [see Warnings and Precautions (5.9) and Adverse Reactions (6.2) ] . 8.5 Geriatric Use In clinical studies of iohexol for CT of the head and body, 52 (17%) of patients were 70 and over. No overall differences in safety were observed between these patients and younger patients. Other reported clinical experience has not identified differences in safety and effectiveness between the elderly and younger patients. Iohexol is substantially excreted by the kidney, and the risk of adverse reactions to iohexol may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. 8.6 Renal Impairment The clearance of iohexol decreases with increasing degree of renal impairment and results in delayed opacification of the urinary system. In addition, preexisting renal impairment increases the risk for acute kidney injury [see Warnings and Precautions (5.4) ] . Iohexol can be removed by dialysis." ], "pregnancy": [ "8.1 Pregnancy Risk Summary Hysterosalpingography is contraindicated in pregnant women due to the potential risk to the fetus from an intrauterine procedure [see Contraindications (4) ]. There are no data with iohexol use in pregnant women to inform any drug-associated risks. Iohexol crosses the placenta and reaches fetal tissues in small amounts (see Data) . In animal reproduction studies, no developmental toxicity occurred with intravenous iohexol administration to rats and rabbits at doses up to 0.4 (rat) and 0.5 (rabbit) times the maximum recommended human intravenous dose (see Data) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Literature reports show that intravenously administered iohexol crosses the placenta and is visualized in the digestive tract of exposed infants after birth. Animal Data Iohexol was neither embryotoxic nor teratogenic in either rats or rabbits at the following dose levels tested: 1 g iodine/kg, 2 g iodine/kg, 4 g iodine/kg in rats, administered intravenously to 3 groups of 25 dams once daily during days 6 through 15 of pregnancy; 0.3 g iodine/kg, 1 g iodine/kg, 2.5 g iodine/kg in rabbits, administered intravenously to 3 groups of 18 rabbits dosed once a day during days 6 through 18 of pregnancy." ], "labor_and_delivery": [ "8.2 Lactation Risk Summary Published literature reports that breast feeding after intravenous iohexol administration to the mother would result in the infant receiving an oral dose of approximately 0.7% of the maternal intravenous dose; however, lactation studies have not been conducted with oral, intrathecal, or intracavity administration of iohexol. There is no information on the effects of the drug on the breastfed infant or on milk production. Iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from the gastrointestinal tract of a breastfed infant. Exposure to iohexol to a breastfed infant can be minimized by temporary discontinuation of breastfeeding (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for iohexol and any potential adverse effects on the breastfed infant from iohexol or from the underlying maternal condition. Clinical Considerations Interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because the potential exposure of the breastfed infant to iodine is small. However, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 10 hours (approximately 5 elimination half-lives) after iohexol injection administration to minimize drug exposure to a breastfed infant." ], "pediatric_use": [ "8.4 Pediatric Use Intrathecal Use The safety and effectiveness of iohexol have been established in pediatric patients aged 2 weeks and older for myelography and CT myelography (lumbar, thoracic, cervical, total columnar) and for CT cisternography. Use of iohexol is supported by controlled clinical studies in adults for myelography, in addition to clinical studies in pediatric patients undergoing myelography. The safety and effectiveness of iohexol have not been established for intrathecal use in pediatric patients less than 2 weeks of age. The safety and effectiveness of iohexol for CT cerebral ventriculography have not been established in pediatric patients. Intra-arterial or Intravenous Use Cardiac Ventriculography, Aortography and Pulmonary Angiography The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for cardiac ventriculography, aortography and pulmonary angiography. Use of iohexol is supported by controlled clinical studies in adults for cardiac ventriculography and aortography, in addition to controlled clinical studies in pediatric patients undergoing cardiac ventriculography, including aortography. Excretory Urography The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for excretory urography. Use of iohexol is supported by controlled clinical studies in adults for urography, in addition to controlled clinical studies in pediatric patients undergoing urography and clinical safety data in pediatric patients down to birth. CT of the Head and Body The safety and effectiveness of iohexol have been established in pediatric patients from birth to 17 years of age for CT imaging of the head and body. Use of iohexol is supported by controlled clinical studies in adults for head and body CT, in addition to clinical studies in pediatric patients undergoing head CT and in 69 pediatric patients undergoing CT of the abdomen after oral administration of diluted iohexol plus intravenous administration of iohexol injection. Selective Coronary Arteriography, Cerebral and Peripheral Arteriography, Intra-arterial Digital Subtraction Angiography, Peripheral Venography and Intravenous Digital Subtraction Angiography The safety and effectiveness of iohexol have not been established in pediatric patients for selective coronary arteriography, cerebral or peripheral arteriography, intra-arterial digital subtraction angiography, peripheral venography and intravenous digital subtraction angiography. Oral or Rectal Use Examination of the GI Tract The safety and effectiveness of iohexol have been established in pediatric patients, from birth to 17 years of age for examination of the GI tract. Use of iohexol is supported by controlled studies in adults for examination of the GI tract, in addition to clinical studies in pediatric patients undergoing examination of the GI tract. CT of the Abdomen and Pelvis in Conjunction with Intravenous Use The safety and effectiveness of iohexol for CT of the abdomen and pelvis have been established in pediatric patients from birth to 17 years of age. Use is supported by clinical trials in adults, in addition to clinical studies in 69 pediatric patients undergoing CT of the abdomen. Intraarticular Use The safety and effectiveness of iohexol have not been established in pediatric patients for arthrography. Body Cavity Use Voiding Cystourethrography Iohexol is indicated for use in pediatric patients from birth to 17 years of age for voiding cystourethrography (VCU). Use for voiding cystourethrography is supported by clinical studies in 51 pediatric patients undergoing VCU. ERCP, Herniography, and Hysterosalpingography The safety and effectiveness of iohexol have not been established in pediatric patients for ERCP, herniography, or hysterosalpingography. In general, the frequency of adverse reactions in pediatric patients was similar to that seen in adults [ s ee Adverse Reactions (6.1) ] . Pediatric patients at higher risk of experiencing adverse events during contrast-medium administration may include those having asthma, a sensitivity to medication and/or allergens, congestive heart failure, a serum creatinine greater than 1.5 mg/dL or those less than 12 months of age. Thyroid function tests indicative of thyroid dysfunction, characterized by hypothyroidism or transient thyroid suppression have been reported following iodinated contrast media administration in pediatric patients, including term and preterm neonates. Some patients were treated for hypothyroidism. After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0 to 3 years of age based on underlying risk factors, especially in term and preterm neonates [see Warnings and Precautions (5.9) and Adverse Reactions (6.2) ] ." ], "geriatric_use": [ "8.5 Geriatric Use In clinical studies of iohexol for CT of the head and body, 52 (17%) of patients were 70 and over. No overall differences in safety were observed between these patients and younger patients. Other reported clinical experience has not identified differences in safety and effectiveness between the elderly and younger patients. Iohexol is substantially excreted by the kidney, and the risk of adverse reactions to iohexol may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function." ], "overdosage": [ "10 OVERDOSAGE The adverse effects of overdosage in intra-arterial or intravenous administration are life-threatening and affect mainly the pulmonary and cardiovascular systems. The symptoms include: cyanosis, bradycardia, acidosis, pulmonary hemorrhage, convulsions, coma and cardiac arrest. Treatment of an overdosage is directed toward the support of all vital functions and prompt institution of symptomatic therapy. Iohexol can be dialyzed." ], "description": [ "11 DESCRIPTION Iohexol, USP is a nonionic radiographic contrast agent available as: Iohexol injection for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular and body cavity use. The chemical name of iohexol, USP is N,N’ -Bis(2,3-dihydroxypropyl)-5-[ N -(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthalamide with a molecular weight of 821.14 (iodine content 46.36%). Iohexol has the following structural formula: Iohexol Injection, USP is a sterile, pyrogen-free, clear, colorless to pale yellow solution available in following concentrations of iodine: Iohexol Injection USP, 300 mg iodine/mL: Each mL contains 647 mg iohexol, USP (providing 300 mg organically bound iodine) and the following inactive ingredients: 0.1 mg edetate calcium disodium, USP; 1.21 mg tromethamine, USP and water for injection. Iohexol Injection USP, 350 mg iodine/mL: Each mL contains 755 mg iohexol, USP (providing 350 mg organically bound iodine) and the following inactive ingredients: 0.1 mg edetate calcium disodium, USP; 1.21 mg tromethamine, USP and water for injection. The pH is adjusted between 6.8 and 7.7 with hydrochloric acid or sodium hydroxide. Iohexol injection contain no preservatives and no ingredient made from a gluten-containing grain (wheat, barley, or rye). Iohexol injection have the following physical properties: Table 21: Physicochemical Properties of Iohexol Injection Dosage Form Concentration (mg iodine/mL) Osmolality * (mOsmol/kg water) Absolute Viscosity (cP) Specific Gravity 20°C 37°C 37°C Injection 300 659 11.48 6.05 1.344 350 774 21.48 12.16 1.4054 * By Freezing Point Depression Osmometer. Iohexol injection has osmolalities from approximately 2.4 times that of plasma (285 mOsmol/kg water) or cerebrospinal fluid (301 mOsmol/kg water) as shown in the above table and are hypertonic. 1" ], "description_table": [ "
Dosage FormConcentration (mg iodine/mL)Osmolality* (mOsmol/kg water)Absolute Viscosity(cP)Specific Gravity
20°C37°C37°C
Injection30065911.486.051.344
350 774 21.4812.16 1.4054
*By Freezing Point Depression Osmometer.
" ], "clinical_pharmacology": [ "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures. 12.2 Pharmacodynamics Intrathecal Administration The initial concentration and volume of the contrast medium, in conjunction with patient manipulation and the volume of cerebrospinal fluid (CSF) into which the contrast medium is placed, will determine the extent of the contrast that can be achieved. Following intrathecal injection in conventional radiography, iohexol injection 180 mg iodine/mL, 240 mg iodine/mL and 300 mg iodine/mL will continue to provide contrast for at least 30 minutes. Slow diffusion of iohexol takes place throughout the CSF with subsequent absorption into the bloodstream. At approximately 1 hour following injection, contrast will no longer be sufficient for conventional myelography. After administration into the lumbar subarachnoid space, computerized tomography shows the presence of contrast medium in the thoracic region in about 1 hour, in the cervical region in about 2 hours and in the basal cisterns in 3 hours to 4 hours. Intravenous or Intra-arterial Administration Following intravenous or intra-arterial administration of iohexol injection, the degree of contrast enhancement is directly related to the iodine concentration of an administered dose; peak iodine blood concentrations occur immediately (15 seconds to 120 seconds) following rapid intravenous injection. The time to maximum contrast enhancement can vary, depending on the organ, from the time that peak blood iodine concentrations are reached to one hour after intravenous bolus administration. When a delay between peak blood iodine concentrations and peak contrast is present, it suggests that radiographic contrast enhancement is at least in part dependent on the accumulation of iodine containing agent within the lesion and outside the blood pool. Oral Administration Orally administered iohexol produces visualization of the gastrointestinal tract. Less than 1% of orally administered iohexol is recovered in the urine, suggesting minimal amounts are absorbed from the normal gastrointestinal tract. This amount may increase in the presence of bowel perforation or bowel obstruction. Intraarticular Administration Visualization of the joint spaces can be accomplished by direct injection of contrast medium. For intraarticular cavities, the injected iohexol is absorbed into the surrounding tissue and subsequently absorbed into systemic circulation. Body Cavity Administration For most body cavities, the injected iohexol is absorbed into the surrounding tissue and subsequently absorbed into systemic circulation. Examinations of the uterus (hysterosalpingography) and bladder (voiding cystourethrography) involve the almost immediate drainage of contrast medium from the cavity upon conclusion of the radiographic procedure. 12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min. Clearance was not dose dependent. Absorption As evidenced by the amount recovered in urine, < 1% of orally administered iohexol is absorbed from the normal gastrointestinal tract. This amount may increase in the presence of bowel perforation or bowel obstruction. Distribution In 16 adult subjects (receiving between 500 mg iodine/kg to 1,500 mg iodine/kg intravenous iohexol) the plasma volume of distribution was 165 (108 to 219) mL/kg. In five adult patients receiving 16 mL to 18 mL of iohexol (180 mg iodine/mL) by lumbar intrathecal injection the plasma volume of distribution was 559 (350 to 849) mL/kg. Elimination Metabolism No significant metabolism, deiodination or biotransformation occurs. Excretion Following intravenous, intra-arterial or intrathecal administration, iohexol is excreted unchanged by glomerular filtration. Approximately 90% of the intravenously injected iohexol dose is excreted within the first 24 hours. Following intravenous or intraarterial administration, peak urine concentration occurs in the first hour after injection." ], "mechanism_of_action": [ "12.1 Mechanism of Action The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures." ], "pharmacodynamics": [ "12.2 Pharmacodynamics Intrathecal Administration The initial concentration and volume of the contrast medium, in conjunction with patient manipulation and the volume of cerebrospinal fluid (CSF) into which the contrast medium is placed, will determine the extent of the contrast that can be achieved. Following intrathecal injection in conventional radiography, iohexol injection 180 mg iodine/mL, 240 mg iodine/mL and 300 mg iodine/mL will continue to provide contrast for at least 30 minutes. Slow diffusion of iohexol takes place throughout the CSF with subsequent absorption into the bloodstream. At approximately 1 hour following injection, contrast will no longer be sufficient for conventional myelography. After administration into the lumbar subarachnoid space, computerized tomography shows the presence of contrast medium in the thoracic region in about 1 hour, in the cervical region in about 2 hours and in the basal cisterns in 3 hours to 4 hours. Intravenous or Intra-arterial Administration Following intravenous or intra-arterial administration of iohexol injection, the degree of contrast enhancement is directly related to the iodine concentration of an administered dose; peak iodine blood concentrations occur immediately (15 seconds to 120 seconds) following rapid intravenous injection. The time to maximum contrast enhancement can vary, depending on the organ, from the time that peak blood iodine concentrations are reached to one hour after intravenous bolus administration. When a delay between peak blood iodine concentrations and peak contrast is present, it suggests that radiographic contrast enhancement is at least in part dependent on the accumulation of iodine containing agent within the lesion and outside the blood pool. Oral Administration Orally administered iohexol produces visualization of the gastrointestinal tract. Less than 1% of orally administered iohexol is recovered in the urine, suggesting minimal amounts are absorbed from the normal gastrointestinal tract. This amount may increase in the presence of bowel perforation or bowel obstruction. Intraarticular Administration Visualization of the joint spaces can be accomplished by direct injection of contrast medium. For intraarticular cavities, the injected iohexol is absorbed into the surrounding tissue and subsequently absorbed into systemic circulation. Body Cavity Administration For most body cavities, the injected iohexol is absorbed into the surrounding tissue and subsequently absorbed into systemic circulation. Examinations of the uterus (hysterosalpingography) and bladder (voiding cystourethrography) involve the almost immediate drainage of contrast medium from the cavity upon conclusion of the radiographic procedure." ], "pharmacokinetics": [ "12.3 Pharmacokinetics Following the intravenous administration of iohexol (between 500 mg iodine/kg to 1,500 mg iodine/kg) to 16 adult subjects, apparent first-order terminal elimination half-life was 12.6 hours and total body clearance was 131 (98 to 165) mL/min. Clearance was not dose dependent. Absorption As evidenced by the amount recovered in urine, < 1% of orally administered iohexol is absorbed from the normal gastrointestinal tract. This amount may increase in the presence of bowel perforation or bowel obstruction. Distribution In 16 adult subjects (receiving between 500 mg iodine/kg to 1,500 mg iodine/kg intravenous iohexol) the plasma volume of distribution was 165 (108 to 219) mL/kg. In five adult patients receiving 16 mL to 18 mL of iohexol (180 mg iodine/mL) by lumbar intrathecal injection the plasma volume of distribution was 559 (350 to 849) mL/kg. Elimination Metabolism No significant metabolism, deiodination or biotransformation occurs. Excretion Following intravenous, intra-arterial or intrathecal administration, iohexol is excreted unchanged by glomerular filtration. Approximately 90% of the intravenously injected iohexol dose is excreted within the first 24 hours. Following intravenous or intraarterial administration, peak urine concentration occurs in the first hour after injection." ], "nonclinical_toxicology": [ "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed with iohexol to evaluate carcinogenic potential. Iohexol was not genotoxic in a series of studies, including the Ames test, the mouse lymphoma TK locus forward mutation assay and a mouse micronucleus assay. Iohexol did not impair the fertility of male or female rats when repeatedly administered at intravenous dosages up to 4 g iodine/kg." ], "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [ "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed with iohexol to evaluate carcinogenic potential. Iohexol was not genotoxic in a series of studies, including the Ames test, the mouse lymphoma TK locus forward mutation assay and a mouse micronucleus assay. Iohexol did not impair the fertility of male or female rats when repeatedly administered at intravenous dosages up to 4 g iodine/kg." ], "clinical_studies": [ "14 CLINICAL STUDIES The safety and effectiveness of iohexol for CT of the head were evaluated in three clinical studies. Each study also used an ionic high-osmolar iodinated contrast agent as a comparator. A total of 280 patients were randomized to administration of either iohexol (n = 142) or the comparator (n = 138). Iohexol patients had a mean age of 52 years (range 16 to 85), 41% were women and were administered a mean of 692 mg iodine/kg (range 337 mg iodine/kg to 1,250 mg iodine/kg) by intravenous injection with iohexol 240 mg iodine/mL (1 study) or 300 mg iodine/mL (2 studies). Efficacy was determined from investigator ratings of quality of contrast enhancement (none, poor, good, or excellent; only scans rated as good or excellent were considered diagnostic). The percentage of iohexol-enhanced scans rated as good or excellent was 100% in the two studies using iohexol injection 300 mg iodine/mL and 79% in the third study using iohexol injection 240 mg iodine/mL." ], "how_supplied": [ "16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Iohexol Injection, USP is clear, colorless to pale yellow solution available in the following presentations: Dosage Form Concentration (mg iodine/mL) Package Size Package Type & Material Sale Unit NDC Injection 300 50 mL Single-Dose Polymer Bottles Carton of 10 80830-2466-2 75 mL Single-Dose Polymer Bottles Carton of 10 80830-2467-2 100 mL Single-Dose Polymer Bottles Carton of 10 80830-2468-2 350 50 mL Single-Dose Polymer Bottles Carton of 10 80830-2471-2 75 mL Single-Dose Polymer Bottles Carton of 10 80830-2472-2 100 mL Single-Dose Polymer Bottles Carton of 10 80830-2473-2 The container closure system components (bottle, stopper and cap) of iohexol injection are not made with natural rubber latex. Storage and Handling Iohexol Injection: Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. May be stored in a contrast media warmer for up to one month, not to exceed 37°C (98.6°F). Protect from light. Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container." ], "how_supplied_table": [ "
Dosage FormConcentration (mg iodine/mL)Package SizePackage Type & MaterialSale UnitNDC
Injection 300 50 mL Single-Dose Polymer Bottles Carton of 10 80830-2466-2
75 mL Single-Dose Polymer BottlesCarton of 1080830-2467-2
100 mLSingle-Dose Polymer BottlesCarton of 1080830-2468-2
350 50 mL Single-Dose Polymer Bottles Carton of 10 80830-2471-2
75 mL Single-Dose Polymer Bottles Carton of 10 80830-2472-2
100 mL Single-Dose Polymer Bottles Carton of 10 80830-2473-2
" ], "information_for_patients": [ "17 PATIENT COUNSELING INFORMATION Hypersensitivity Reactions Advise the patient concerning the risk of hypersensitivity reactions that can occur both during and after iohexol injection administration. Advise the patient to report any signs or symptoms of hypersensitivity reactions during the procedure and to seek immediate medical attention for any signs or symptoms experienced after discharge [see Warnings and Precautions (5.3) ]. Advise patients to inform their physician if they develop a rash after receiving iohexol injection [see Warnings and Precautions (5.12) ]. Acute Kidney Injury Advise the patient concerning appropriate hydration to decrease the risk of contrast-induced acute kidney injury [see Warnings and Precautions (5.4) ] . Extravasation If extravasation occurs during injection, advise patients to seek medical care for progression of symptoms [see Warnings and Precautions (5.7) ]. Lactation Advise a lactating woman that interruption of breastfeeding is not necessary. However, to avoid any exposure, a lactating woman may consider pumping and discarding breast milk for 10 hours after iohexol injection administration [see Use in Specific Populations (8.2) ]. Thyroid Dysfunction Advise parents/caregivers about the risk of developing thyroid dysfunction after iohexol injection administration. Advise parents/caregivers about when to seek medical care for their child to monitor for thyroid function [see Warnings and Precautions (5.9) ]. Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 382110, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 06-2026-01" ], "package_label_principal_display_panel": [ "PRINCIPAL DISPLAY PANEL NDC 80830-2466-1 Iohexol Injection USP, 300 mgI/mL 50 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2466-2 Iohexol Injection USP, 300 mgI/mL Carton Label (10 x 50 mL Bottles) Rx only Amneal Pharmaceuticals LLC Amneal Pharmaceuticals LLC NDC 80830-2467-1 Iohexol Injection USP, 300 mgI/mL 75 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2467-2 Iohexol Injection USP, 300 mgI/mL Carton Label (10 x 75 mL Bottles) Rx only Amneal Pharmaceuticals LLC NDC 80830-2468-1 Iohexol Injection USP, 300 mgI/mL 100 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2468-2 Iohexol Injection USP, 300 mgI/mL Carton Label (10 x 100 mL Bottles) Rx only Amneal Pharmaceuticals LLC NDC 80830-2471-1 Iohexol Injection USP, 350 mgI/mL 50 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2471-2 Iohexol Injection USP, 350 mgI/mL Carton Label (10 x 50 mL Bottles) Rx only Amneal Pharmaceuticals LLC NDC 80830-2472-1 Iohexol Injection USP, 350 mgI/mL 75 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2472-2 Iohexol Injection USP, 350 mgI/mL Carton Label (10 x 75 mL Bottles) Rx only Amneal Pharmaceuticals LLC NDC 80830-2473-1 Iohexol Injection USP, 350 mgI/mL 100 mL Bottle Label Rx only Amneal Pharmaceuticals LLC NDC 80830-2473-2 Iohexol Injection USP, 350 mgI/mL Carton Label (10 x 100 mL Bottles) Rx only Amneal Pharmaceuticals LLC 1 1 1 2 2 LL 3 2 5 6 8 8" ], "set_id": "ff9456ef-c45a-450d-9004-a684af2bcc59", "id": "d73504e3-4f96-4751-ae9f-fa6201b28640", "effective_time": "20260630", "version": "11", "openfda": { "application_number": [ "ANDA217737" ], "brand_name": [ "Iohexol" ], "generic_name": [ "IOHEXOL" ], "manufacturer_name": [ "Amneal Pharmaceuticals Private Limited" ], "product_ndc": [ "80830-2466", "80830-2467", "80830-2468", "80830-2471", "80830-2472", "80830-2473" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRATHECAL", "INTRAVASCULAR", "INTRAVENOUS", "ORAL", "RECTAL" ], "substance_name": [ "IOHEXOL" ], "spl_id": [ "d73504e3-4f96-4751-ae9f-fa6201b28640" ], "spl_set_id": [ "ff9456ef-c45a-450d-9004-a684af2bcc59" ], "package_ndc": [ "80830-2467-1", "80830-2467-2", "80830-2468-1", "80830-2468-2", "80830-2466-1", "80830-2466-2", "80830-2471-1", "80830-2471-2", "80830-2472-1", "80830-2472-2", "80830-2473-1", "80830-2473-2" ], "is_original_packager": [ true ], "nui": [ "N0000180185", "N0000010258" ], "pharm_class_epc": [ "Radiographic Contrast Agent [EPC]" ], "pharm_class_moa": [ "X-Ray Contrast Activity [MoA]" ], "unii": [ "4419T9MX03" ] } } ] }